Table 3 Demographics of typical PFF group and atypical PFF group
From: Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
Vancouver type B1 fracture distribution | Typical PFF (n = 36, 87%) | % | Atypical PFF (n = 5, 13%) | % | p-value |
|---|---|---|---|---|---|
Mean age | 79.5 (54-94) | 80 (67-85) | 0.24 | ||
Gender (male/female) | 9/27 | 0/5 | 0.26 | ||
BMI – body mass index | 24.9 ± 3.3 | 23.2 ± 1.8 | 0.53 | ||
Chronic diseases | |||||
Diabetes | 7 | 19.44% | 0 | 0% | 0.37 |
Rheumatoid arthritis | 1 | 2.78% | 1 | 20% | 0.21 |
Hypertension | 35 | 97.22% | 5 | 100.0% | 0.87 |
Thyroid disease | 5 | 13.89% | 2 | 40% | 0.66 |
Malignancy | 3 | 8.33% | 0 | 0% | 0.62 |
Neurologic disease | 9 | 25.00% | 2 | 40% | 0.29 |
Osteoporosis | 16 | 44.44% | 4 | 80% | 0.20 |
History of bisphosphonate use | 5 | 13.88% | 4 | 80% | 0.01 |
Duration of bisphosphonate use (years average) | 4 ± 0.7 | 8.2 ± 5.5 | 0.01 | ||
Corticosteroid use | 1 | 2.78% | 0 | 0% | 0.87 |
Stem position | |||||
Central | 32 | 88.89% | 4 | 80% | 0.39 |
Varus | 2 | 2.78% | 1 | 20% | 0.29 |
Valgus | 2 | 2.78% | 0 | 0% | 0.76 |
Cemented stem | 31 | 86.11% | 5 | 100% | 0.50 |
Cementless stem | 5 | 13.89% | 0 | 0% | 0.50 |
Duration of healing process (months average) | 5.7 ± 1.4 | 9.2 ± 4.7 | 0.27 | ||
Interval between prior arthroplasty and PFF (years average) | 10 ± 8 | 6 ± 3.5 | 0.26 |